President and CEO of Cassava Sciences Inc (30-Year Financial, Insider Trades) Remi Barbier (insider trades) bought 10,000 shares of SAVA on 09/24/2020 at an average price of $9.59 a share. The total cost of this purchase was $95,900.
Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Cassava Sciences Inc has a market cap of $241.950 million; its shares were traded at around $9.71 . Cassava Sciences Inc had annual average EBITDA growth of 32.30% over the past five years. GuruFocus has detected 1 severe warning sign with Cassava Sciences Inc. .
CEO Recent Trades:
- President and CEO Remi Barbier bought 10,000 shares of SAVA stock on 09/24/2020 at the average price of $9.59. The price of the stock has increased by 1.25% since.
CFO Recent Trades:
- CFO Eric Schoen bought 12,000 shares of SAVA stock on 09/17/2020 at the average price of $7.03. The price of the stock has increased by 38.12% since.
Directors and Officers Recent Trades:
- Director Sanford Robertson bought 36,281 shares of SAVA stock on 09/18/2020 at the average price of $8.92. The price of the stock has increased by 8.86% since.
- Director Sanford Robertson bought 213,719 shares of SAVA stock on 09/17/2020 at the average price of $6.98. The price of the stock has increased by 39.11% since.
For the complete insider trading history of SAVA, click here
.
